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One of the most promising strategies to treat cancer is attacking it with viruses. Virus can kill
tumor cells specifically or act as carriers that deliver normal genes into cancer cells. A model for virus
therapy of cancer is investigated and some of its predictions are in agreement with results obtained
from experimental tumors. Furthermore, the model reveals an oscillatory (periodic or aperiodic)
response of tumor cells and virus populations which may difficult clinical prognosis. These results
suggest the need for new in vivo and in vitro experiments aiming to detect this oscillatory response.
PACS numbers: 87.17.Aa,87.18.Hf,87.17.Ee,87.15.Vv
In the last few years, in which most of the research
in molecular biology of cancer focused in new target
genes and potential biomarkers, promising roads for tu-
mor treatment such as gene therapy, virus and antian-
giogenic drugs have been openned [1, 2]. However, most
of the clinically-used cancer therapies have been devel-
oped empirically [1], and therefore mathematical models
might be complementary (maybe necessary) tools for the
understanding of the dynamics of drug response in the
organism. Noticeable examples of such modeling are the
recent works of Scalerandi et al. [3], in which the action
of different antiangiogenic drugs was simulated, of Wu
et al. [4] and Wein et al. [5], concerning the spreading
of a virus that replicates selectively in tumor cells, and
of Kozusko et al., addressing cancer cell growth and re-
sponse to treatment with cyclic-specific chemotherapeu-
tic drugs [6].
Current cancer therapy is based on damaging DNA by
irradiation or chemicals. However, cells lacking p53 tu-
mor supressor gene are unable to respond to DNA dam-
age by inducing cell cycle arrest or apoptosis, frequently
becoming refractary to chemotherapy or radiation. These
cells occur in more than 50% of all human cancers, and
hence it is imperative to develope new forms of treat-
ment. Viruses can be used to trigger a DNA damage
response without damaging cellular DNA and to selec-
tively replicate in and lyse p53-deficient human tumor
cells [7, 8]. Other potential oncolytic agents were re-
cently tested. Among them are the reovirus, which can
be used in more than 50% of all human tumors having
an activated Ras signaling pathway [11], and the avian
Newcastle disease virus [12], a genetically altered herpes
simplex virus, which kill cancer cells exhibiting an altered
p16/pRB tumor suppressor pathway [13]. In particular,
clinical trials in humans using Delta-24 RGD adenovirus,
an agent with unprecedented success in the treatment of
gliomas [9], are currently being designed. Also, since
genetically engineered virus can be selected to kill only
cancer cells, virus therapy might be more specific than
standard DNA-damaging drugs associated to many toxic
effects on the normal cells [10].
In this letter, a model for virus therapy of cancer
is investigated and a few of their predictions are com-
pared with results from experimental tumors. The
model, based on a previous one recently proposed by
us for the avascular growth of tumors [14] and applied
to chemotherapy modelling [15], combines macroscopic
reaction-diffusion equations for the nutrients and virus
with microscopic stochastic rules governing the actions
of individual cancer cells. It seems to be appropriated to
study the response of cancers accessible to direct intratu-
moral virus injection (primary brain tumors and cancers
of the head and neck, for example), but mainly their dis-
tant metastatic outgrowths. Its prime advantages are the
use of both, an individual-based framework in which the
fate of each cancer cell is traced, and a set of stochastic
rules for cell actions as a simple effective kinetic cellular
model describing the population dynamics of interacting
cells [16, 17].
The tissue, represented by a square lattice, is fed by
a single capillary vessel at i = 0, the top of the lat-
tice. The model considers four different cell populations:
normal σn, uninfected σc, infected σv and dead σd tu-
mor cells. In contrast to the normal and dead tumor
cells, one or more cancer cells can pile up in a given site.
Thus, the cell populations in any site, with coordinates
~x = (i, j), i, j = 0, 1, . . . , L, assume one of the possi-
ble values σn(~x), σd(~x) = 0, 1 and σc(~x), σv(~x) = 0, 1, . . ..
Initially, a single cancer cell at ~x = (d, L/2) is introduced
in the normal tissue. The row i = L + 1 constitutes the
external border of the tissue. The evolution rules imple-
mented in our model are the following:
Nutrient evolution.—The nutrients are divided into
two classes: directly used, N(~x, t), or not, M(~x, t), for
DNA synthesis. Both, N and M , are the stationary so-
lutions of the simplest (linear with constant coefficients)
dimensionless reaction-diffusion equation
∂H
∂t
= ∇2H − α2Hσn − λHα
2H(σc + σv) (1)
in which H represents the nutrient fields. Distinct nutri-
ent consumption rates for normal and cancer cells, char-
acterized by factors λN and λM (λN > λM ), are assumed.
2(see ref. [14] for the complete variable transformations).
Also, it is assumed that infected cancer cells sustain their
metabolism until lysis.
These equations satisfy periodic and Neumann bound-
ary conditions along the horizontal axis and at the border
of the tissue (i = L), respectively. At the capillary vessel
(i = 0) N = M = 1, representing the continuous and
fixed supply of nutrients provided by the blood flow.
Cell dynamics.—Each cancer cell, randomly selected
with equal probability, can carry out one of three actions.
1.Division. Uninfected cancer cells divide by mitosis
with probability
Pdiv(~x) = 1− exp
[
−
(
N(~x)
σc(~x)θdiv
)2]
(2)
determined by the concentration per cancer cell of the
nutrients N necessary for DNA synthesis. The parame-
ter θdiv controls the shape of Pdiv. If the chosen cell is
inside the tumor, its daughter will pile up at that site,
and σc(~x) → σc(~x) + 1. Otherwise, if the selected cell is
on the tumor border, its daughter will occupy at random
one of their normal or necrotic nearest neighbor sites ~x′.
Thus, σc(~x′) = 1 and σn,d(~x′) = 0. In contrast, an in-
fected cancer cell does not divide since its slaved cellular
machinery is focused on virus replication.
2.Migration. Only uninfected cancer cells migrate with
probability
Pmov(~x) = 1− exp
[
−σc(~x)
(
N(~x)
θmov
)2]
. (3)
A selected cell will move to a randomly chosen nearest
neighbor site ~x′. In terms of cell populations σc(~x′) →
σc(~x′)+1, σc(~x)→ σc(~x)−1, σn,d(~x) = 0, or σn,d(~x) = 1
if σc(~x) = 1.
3.Death. Uninfected cancer cells die with probability
Pdel(~x) = exp
[
−
(
M(~x)
σc(~x)θdel
)2]
(4)
determined by the concentration per cancer cell of the nu-
trients M present on the cell’s microenvironment. This
Gaussian distribution has a variance fixed by the param-
eter θdel. Clearly, if the chosen cell dies σc(~x)→ σc(~x)−1
and σd(~x′) = 1 when (σc + σv) vanishes.
Infected cancer cells mainly die by lysis, and the death
due to insufficient nutrient supply is neglected. So, an
infected cell die with probability
Plysis(~x) = 1− exp
(
−
Tinf
Tl
)
(5)
where Tinf is the time since the infection and Tl is the
characteristic period for cell lysis. Again, after lysis
σv(~x) → σv(~x) − 1 and σd(~x′) = 1 when (σc + σv) van-
ishes.
Virus spreading.—The lysis of each infected cancer cell
releases v0 virus to the extra-cellular medium. A ran-
dom fraction of these virus remains on the site of the
lysed cell, and the rest is equally distributed among its
nearest neighbors. Taken these sources into account,
the time evolution of virus concentration is given by
the quasi-stationary solutions of the discrete reaction-
diffusion equation
v(~x, t+1) = v(~x, t)+
Dv
4
∑
<~x,~x′>
[v(~x′, t)−v(~x, t)]−γvv(~x, t).
(6)
Here, Dv is the virus diffusion constant, γv is the vi-
ral clearance rate and the sum, representing the discrete
Laplacian on the square lattice, extends over all the near-
est neighbors of the site ~x. In all simulations, Eq.( 6)
was iterated 100 times at each time step, and Dv and
γv were varied on the interval [0, 1]. Periodic boundary
conditions along the y-axis and Neumann boundary con-
ditions at the border of the tissue (i = L) and at the
capillary vessel (i = 0) were used for the virus.
Free virus can infect a tumor cell with probability
Pinf (~x) = 1− exp
[
−
(
v(~x)
σc(~x)θinf
)2]
, (7)
a sigmoidal function of the local virus concentration per
cancer cell controlled by the parameter θinf , the efficacy
of virus infection.
The virus therapy begins when the tumor attains a
growth N0 and consists in a single virus injection. In
the direct intratumoral (intravenous) administration an
uniforme virus concentration V = v0 = 1 over the entire
tumor (tissue) is supplied. This approach corresponds
to the experimental protocols used in severe combined
immune deficient (SCID) mice [11] and in vitro essays [7,
8].
Results and discussion.—Simulations in lattices with
linear size L = 500 have been done for each morphology
(compact, papillary and ramified) reproduced by our pre-
vious model [14] and commonly observed in real tumors.
The corresponding fixed parameters are reported in ta-
ble I, whereas those controlling virus therapy, namely, Dv
(virus diffusion coefficient), γv (viral clearance rate), θinf
(efficacy of virus infection) and Tl (characteristic time for
cell lysis) were varied. Since the main results are qual-
itatively the same for all morphology types, only those
obtained for compact tumors will be reported here for
brevity.
Figure 1 shows the total number of uninfected cancer
cells as a function of time for different virus diffusion and
clearance rates. Without treatment, the progress in time
of cancer cell populations for all the simulated patterns
grows accordingly Gompertz curves [14]. In the case of
a succesfull therapy the tumor mass is completely erad-
icated a few time steps after virus injection. However,
3TABLE I: Parameter values used in the simulations.
Morphology λN λM α θdiv θdel θmov
compact 25 10 2/L 0.3 0.03 ∞ (no migration)
papillary 200 10 2/L 0.3 0.03 ∞
ramified 200 10 3/L 0.3 0.01 ∞
FIG. 1: Temporal evolution of the number of cancer cells Nc
with and without virus therapy for the compact case.
it is worthwhile to notice that in addition to the virus
oncolytic activity (θinf and Tl), its spreading properties
(Dv and γv) are key features which determine success
of the treatment. Indeed, a smaller virus diffusion con-
stant and a greater clearence rate lead to an unsucces-
full therapy. Moreover, after a significant inicial decrease
in uninfected cancer cells following virus injection, the
tumor grows faster than without treatment. Such re-
sult agrees with the claim that cancer cells facing severe
threats can trigger adaptation mechanisms as an inte-
grated defense program similar to those observed in bac-
terial colonies [18]. A tumor submitted to therapeutic
approaches which do not lead to its complete eradica-
tion may pogressively become more resistant, aggressive
and malignant (more invasive), as it is well known in the
clinical practice. These results address the central is-
sue concerning the effect of the host immune response on
virus therapy, which for human adenoviruses can not be
investigated through any appropriate animal model [8].
An immune response directed at free virus and late viral
antigens expressed on the surface of infected cancer cells
can be modeled by an increase in γv and the introduc-
tion of an additional probability to the death of infected
cells, respectively. For very small γv values the tumor is
eradicated with an unique dose, in agreement with the
essays performed for immune deficient (SCDI) [11] and
athymic [8] mice. In turn, for the same dose but higher
values of γv, more frequent virus injections are necessary
to eradicate the tumor, again as it was observed for syn-
geneic immune-competent C3H mice in Ref. [11].
A striking and novel result shown in Figure 1 is the
FIG. 2: Snapshots of cancer cell (left) and virus (right) pat-
terns at the time steps indicated by the arrows in Fig. 1.
Virus and cancer cells concentrations are depicted in gray
scale with darker levels corresponding to higher values. Dead
cancer cells are depicted in black. In (e) groups of dl1520-
infected HCT116 tumor cells (dark cells) bordering uninfected
and necrotic tissue are shown. In the boxed area the necrotic
cells correspond to the lighter region. (Taken from Ref. [19])
possibility of an oscillatory behavior for both virus and
cancer cell populations. It contrasts to the long-term,
spatially uniform profiles for cells and free virus reached
through damped oscillations obtained by Wu et al. [4].
Instead, the total number of virus, uninfected and in-
fected cancer cells undergo growing (unstable) oscilla-
tions, as shown in Figure 2. Similar patterns exhibit-
ing necrotic regions behind expanding fronts of infected
cancer cells have been found by Heise et al. [19] (Fig.
2(e)). An oscillatory dynamics may turn innappropri-
ate to monitor the therapy at predefined time intervals,
difficulting clinical prognosis. A central feature of such
oscillations is that they are not generated by whatso-
ever time delay between virus infection and cell lysis,
as required in Ref. [5]. In fact, our simulations demon-
strate that for a vanishing Tl this oscillatory behavior
is sustained and, mainly, the effectiveness of virus ther-
apy is largely increased. Furthermore, in this region
of parameter space, a single intratumoral virus injec-
tion can result in a complete tumor regression with a
continously decreasing probability as the clearance rate
increases. Thus, the experimentally observed outcomes
for reovirus [11] and adenovirus [8] therapies, in which
the complete regression of tumors occurs in 60 to 80%
of the mice, seems to correspond to that region of the
model parameter space. The complete parameter sub-
space θinf , γv will be reported elsewhere.
Additionally, our results suggest that virus treatment
may be more effective against highly invasive papillary
4tumors (e. g. glioblastoma multiforme or trichoblas-
toma), since the cells in such tumors grow slowly due
to nutrient limitation. This finding contrast with the
conjecture that very low cell densities at the periphery of
the ramified tumors may prevent further spreading of the
wave of virus infection [5]. The differences between the
predictions of our model and those in Refs. [4, 5], namely,
oscillations without time delay and sustained wave infec-
tion at low cell densities, probably arise from the com-
bined use of macroscopic equations and stochastic mi-
croscopic dynamics for discrete tumor cells, instead of
partial differential equations (PDEs). The interplay be-
tween interactions and fluctuations inherent to the dis-
crete microscopic components of the system may lead to
collective behaviors unrevealed by a PDE based model
[20].
Figure 3 provides further comparison among model
predictions and data for virus therapy of tumors in mice.
It shows the evolution in time of the simulated number
of uninfected tumor cells after virus infection for distinct
virus oncolytic activity. The insets show the tumor pop-
ulation and volume size ratios. These ratios are defined
as the uninfected cancer cell numbers and tumor volumes
normalized by their values at the time of virus injection,
respectively. Also, in order to build this figure a time
for cancer cells to pass through the DNA synthesis phase
of the cell cycle of about 10 h [21] was assumed, mean-
ing that the time steps in the simulations correspond to
about 4 − 5 h. In the inset (b) of Fig. 3, the experi-
mental data correspond to the effects of three different
virus (a wild-type and UV-inactivated adenovirus, and a
mutant adenovirus dl1520) on C33A human cervical tu-
mors xenografts grown subcutaneously in SCID mice [8].
These experiments may be simulated in our approach
by associating distinct values for θinf to different virus,
whereas the virus diffusion constants and clearance rates
are kept fixed since only one unique experimental model
(mouse and implanted tumor) is considered. Remark-
ably, the predictions of the present model are in good
quantitative agreement with the experimental data.
In summary, a model combining macroscopic reaction-
diffusion equations for the nutrients and virus with micro-
scopic stochastic rules governing the actions of the cancer
cells was proposed in order to describe the effects of virus
on tumor growth. The simulational results of the model
are consistent with the experimental findings for virus
therapy. Moreover, they reveal an oscillatory (periodic or
aperiodic) response of tumor cells and virus populations
on an intermediate region of the model parameter space
(Dv, γv). In this region, a single intratumoral injection
of virus can result in a complete tumor regression with a
continously decreasing probability as the clearance rate
increases. Such oscillations, which may difficulty clinical
prognosis, suggest the need for new in vivo and in vitro
experiments aiming to detect this oscillatory response.
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FIG. 3: Temporal evolution of the number of uninfected can-
cer cells for treatments using virus of distinct oncolytic activ-
ities. The arrow indicates the time of virus injection. Inset
(A) shows the simulated cancer cell population ratios, and the
inset (B), taken from Ref. [8], exhibits the C33A cells (p53−)
volume ratios after virus injection. In both insets, the ratios
5 weeks after virus injection were evaluated.
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